Sequencing-Based Measurable Residual Disease Testing in Acute Myeloid Leukemia.
Front Cell Dev Biol
; 8: 249, 2020.
Article
em En
| MEDLINE
| ID: mdl-32457898
ABSTRACT
Next generation sequencing (NGS) methods have allowed for unprecedented genomic characterization of acute myeloid leukemia (AML) over the last several years. Further advances in NGS-based methods including error correction using unique molecular identifiers (UMIs) have more recently enabled the use of NGS-based measurable residual disease (MRD) detection. This review focuses on the use of NGS-based MRD detection in AML, including basic methodologies and clinical applications.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Ano de publicação:
2020
Tipo de documento:
Article